relaxin


Also found in: Dictionary, Thesaurus, Acronyms, Encyclopedia, Wikipedia.

re·lax·in

(rē-lak'sin),
A polypeptide hormone secreted by the corpora lutea of mammalian species during pregnancy. Facilitates the birth process by causing a softening and lengthening of the pubic symphysis and cervix; it also inhibits contraction of the uterus and may play a role in timing of parturition.
[relax + -in]

relaxin

(rĭ-lăk′sĭn)
n.
A female hormone secreted by the corpus luteum that helps soften the cervix and relax the pelvic ligaments in childbirth.

relaxin

[rilak′sin]
a hormone obtained from the corpora lutea of swine and used to relax the pelvic ligaments and dilate the cervix during labor. The medication has also been used to treat dysmenorrhea.

re·lax·in

(rĕ-lak'sin)
Polypeptide hormone secreted by the corpora lutea of mammalian species during pregnancy; facilitates birth process by softening and lengthening the pubic symphysis and cervix.

relaxin

A polypeptide found in the corpus luteum of various mammals that softens the neck of the womb (cervix) and relaxes the pubic joint of the pelvis to ease childbirth. Relaxin has not been proved to occur in humans.

relaxin,

n hormone responsible for softening and relaxing muscles, tendons, and ligaments during pregnancy in preparation for labor and delivery.

relaxin

a factor that produces relaxation of the symphysis pubis and dilatation of the cervix uteri in certain animal species including pigs, cattle, dogs and cats. Produced in the corpus luteum of pregnancy.
References in periodicals archive ?
The recognition of this problem by the international cardiology community underscores the important need for new therapies and the promise that relaxin holds for patients.
Corthera's Pre-RELAX-AHF / RELAX-AHF study is a Phase II/III, multicenter, randomized, double-blind, placebo-controlled, parallel-group, international trial designed to evaluate the efficacy and safety of relaxin for the treatment of AHF.
Relaxin is a naturally occurring peptide hormone that acts as a targeted vasodilator with demonstrated systemic and renal hemodynamic effects.
Relaxin is a naturally occurring peptide hormone that acts as a moderately potent and targeted vasodilator.
patent covering the use of relaxin as a pregnancy indicator in the canine.
6 million for the comparable period in 2002, which included a one-time charge of $312,000 related to the Relaxin program and a $2 million in-process R&D charge related to the in-license of Velac.
We believe that relaxin continues to hold the promise of being a potentially important new therapy for a wide range of diseases and conditions.
F H Faulding & Co Limited (Faulding) today announced that Connetics Corporation's (Connetics) US Phase III clinical trial investigating recombinant human relaxin for the treatment of diffuse scleroderma, a rare life-threatening disease, failed to achieve the desired efficacy outcome.
8 million reversal of a reserve relating to the relaxin program established in the second quarter of 2001, the net loss for the 2001 fourth quarter was $5.
Connetics Corporation (Nasdaq:CNCT) today announced that a Phase III trial investigating recombinant human relaxin in the treatment of diffuse systemic sclerosis, also known as scleroderma, did not meet its primary endpoint.